NovaBay Pharmaceuticals Reports Fourth Quarter Financial Results and 2013 Clinical and Business Update

[at noodls] – Well Positioned in 2013 with Three Phase 2b Clinical Trials for Conjunctivitis, Impetigo and UCBE Advancing EMERYVILLE, Calif., March 14, 2013 — NovaBay Pharmaceuticals, Inc. (NYSE MKT:NBY), a biotechnology … more

View todays social media effects on NBY

View the latest stocks trending across Twitter. Click to view dashboard

See who NovaBay is hiring next, click here to view